Senescent Cell Heterogeneity Makes Universal Senolytics Impossible — We Need Tissue-Specific Clearance

The senolytic field operates on a dangerous assumption: that senescent cells are a single target. They are not. A senescent fibroblast in skin shares almost nothing with a senescent macrophage in visceral fat or a senescent astrocyte in the hippocampus. The SASP profile differs. The anti-apoptotic dependencies differ. The BCL-2 family member keeping each alive differs.

Dasatinib + Quercetin works in adipose tissue. It barely touches senescent endothelial cells. Navitoclax hits BCL-2/BCL-xL dependent cells but causes thrombocytopenia because platelets depend on BCL-xL too. The "broad spectrum senolytic" is a pipe dream — it's like designing one antibiotic for all bacteria.

Hypothesis: Effective senolytic therapy will require tissue-specific cocktails guided by single-cell transcriptomic profiling of each patient's senescent cell landscape. The minimum viable senolytic panel will include 4-6 agents targeting distinct anti-apoptotic dependencies. Within 5 years, "senolytic profiling" will be a standard diagnostic, analogous to tumor molecular profiling in oncology.

Testable prediction: Single-cell RNA-seq of senescent cells from the same organism across 5+ tissues will reveal <30% overlap in their anti-apoptotic gene expression signatures. Childs et al. (2017, Nature Reviews) laid the groundwork; we need the atlas now.